Last reviewed · How we verify

NCT04861519: AutocathFFR

Pivotal, Single-arm Clinical Trial to Assess the Efficacy and Safety of the MedHub AutocathFFR Software Device

Completed Last updated 26 March 2024
What this trial tests

trial testing Collecting invasive FFR measurements. in Stable Angina in 308 participants. Completed in 31 December 2021.

Timeline
9 May 2021
Primary endpoint
30 October 2021
31 December 2021

Quick facts

Lead sponsorMedhub Ltd.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment308
Start date9 May 2021
Primary completion30 October 2021
Estimated completion31 December 2021
Sites3 locations across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Medhub Ltd.

Who can join

18 and older, any sex, with Stable Angina or Unstable Angina. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective (analysis of retrospective data), multi-center, observational, single-arm study. This structure was selected as the "worst case" due to the fact that it represents real life usage of invasive FFR measurement is performed mostly in "gray zone" cases, which are that their severity cannot be determined intuitively and based on the physician eyeball. By using real-world historical data of invasive FFR, the analysis of the obtained data can ensure that the study results are expected to include invasive FFR results that are in the grey zone, when invasive FFR is used in real life and represent the real expected use of the product. Furthermore, the analysis of the data obtained in the studies with these similar devices measuring FFR obtained from angiograms was actually performed in a retrospective manner. That is, although the angiographic images and pressure wire recordings were obtained in real-time, due to the need to mark the vessel in real-time and obtain specific projections during the procedure without which the FFR cannot be calculated, the primary endpoint (sensitivity and specificity) and accuracy were determined in all studies by a post-hoc review by a similar independent QCA core laboratory. The invasive FFR data, as well as the software generated FFR data were reviewed post-hoc by a core laboratory or even at the company.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Performance of a novel artificial intelligence software developed to derive coronary fractional flow reserve values from diagnostic angiograms.
    Ben-Assa E, Abu Salman A, Cafri C, Roguin A, et al · · 2023 · cited 11× · PMID 37855304 · DOI 10.1097/mca.0000000000001305

Verify or expand the search:

Other trials of Collecting invasive FFR measurements.

Trials testing the same drug.

Other recruiting trials for Stable Angina

Currently open trials in the same condition.

Other Medhub Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04861519.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing